Medline

At a glance

Medline reported 2025 revenue of $28.43B, up 11.5% from $25.51B in 2024. Over 2 years since 2023 ($23.23B), that is growth of about 10.6% a year. Operating margin was 7.8%, up from 5.4% in 2023. 2025 was the highest revenue year in this period.

In the last 12 months 10 insiders reported 4 open-market purchases ($515M) and 15 sales ($8.2B). 1 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $1.22B by 10% owner Bx Mozart Ml-2 Holdco L.P. on Jun 1, 2026. Net, insiders were sellers of $7.68B.

Medline filed 9 current reports (Form 8-K) in the last 12 months, most often for officer or director change (3), results of operations (3), material agreement (2) and regulation fd disclosure (1). The latest officer or director change was reported on Oct 15, 2026. It reported a material agreement or a completed acquisition or disposal 2 times.

5 of the 20 investors tracked here held Medline at the last quarter end, worth $1.12B combined. It is the largest weight for Lone Pine Capital (5.1% of its portfolio), followed by Soros Fund Management (1.1%). New this quarter: Bridgewater Associates. Added: Lone Pine Capital and Soros Fund Management. Reduced: Viking Global Investors.

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.